Svetlana G Vassilieva
Overview
Explore the profile of Svetlana G Vassilieva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
41
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klementieva N, Lunev E, Shmidt A, Loseva E, Savchenko I, Svetlova E, et al.
Nucleic Acid Ther
. 2024 Jan;
34(2):90-99.
PMID: 38215303
RNA interference (RNAi)-based therapeutics hold the potential for dominant genetic disorders, enabling sequence-specific inhibition of pathogenic gene products. We aimed to direct RNAi for the selective suppression of the heterozygous...
2.
Egorova T, Polikarpova A, Vassilieva S, Dzhenkova M, Savchenko I, Velyaev O, et al.
Mol Ther Methods Clin Dev
. 2023 Jul;
30:161-180.
PMID: 37457303
Duchenne muscular dystrophy (DMD) is a severe hereditary disease caused by a deficiency in the dystrophin protein. The most frequent types of disease-causing mutations in the DMD gene are frameshift...
3.
Egorova T, Galkin I, Velyaev O, Vassilieva S, Savchenko I, Loginov V, et al.
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298068
Mutations that prevent the production of proteins in the gene cause Duchenne muscular dystrophy. Most frequently, these are deletions leading to reading-frame shift. The "reading-frame rule" states that deletions that...
4.
Polikarpova A, Egorova T, Lunev E, Tsitrina A, Vassilieva S, Savchenko I, et al.
Front Genome Ed
. 2023 Apr;
5:1034720.
PMID: 37077890
The development of personalized medicine for genetic diseases requires preclinical testing in the appropriate animal models. GNAO1 encephalopathy is a severe neurodevelopmental disorder caused by heterozygous mutations in the gene....
5.
Starikova A, Skopenkova V, Polikarpova A, Reshetov D, Vassilieva S, Velyaev O, et al.
Sci Rep
. 2022 Jan;
12(1):848.
PMID: 35039573
High expectations have been set on gene therapy with an AAV-delivered shortened version of dystrophin (µDys) for Duchenne muscular dystrophy (DMD), with several drug candidates currently undergoing clinical trials. Safety...
6.
Danilov K, Vassilieva S, Polikarpova A, Starikova A, Shmidt A, Galkin I, et al.
Exp Cell Res
. 2020 May;
392(2):112033.
PMID: 32360435
AAV-delivered microdystrophin genes hold great promise for Duchenne muscular dystrophy (DMD) treatment. It is anticipated that the optimization of engineered dystrophin genes will be required to increase the efficacy and...
7.
Egorova T, Zotova E, Reshetov D, Polikarpova A, Vassilieva S, Vlodavets D, et al.
Dis Model Mech
. 2019 Apr;
12(4).
PMID: 31028078
Exon skipping is a promising strategy for Duchenne muscular dystrophy (DMD) disease-modifying therapy. To make this approach safe, ensuring that excluding one or more exons will restore the reading frame...